Drug Insights

The Synapse User's Toolkit: Tips for Searching Glipizide

15 March 2024
2 min read

Glipizide, the petit but potent drug compound, born out of the laboratories of the esteemed pharmaceutical company Pfizer Inc., has become a reliable and formidable weapon in the battle against hyperglycemia and type 2 diabetes mellitus. Functioning as a modulator, this molecule works its magic by targeting the SUR protein, the gatekeeper of pancreatic beta cells, and stimulates insulin secretion. Combining this medication with other treatments, such as dietary changes and exercise, has proven to be an effective way to manage and regulate blood sugar levels in patients. When it comes to managing type 2 diabetes, glipizide has proven itself time and again to be an ally in the fight for better health and a better life. Click on the image below to begin the exploration journey of Glipizide through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

MRT-8102 Preclinical Trials: Exploring Monte Rosa's Innovative NEK7-Targeted Molecular Glue Degrader
Latest Hotspot
3 min read
MRT-8102 Preclinical Trials: Exploring Monte Rosa's Innovative NEK7-Targeted Molecular Glue Degrader
15 March 2024
Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.
Read →
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
Hot Spotlight
7 min read
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
15 March 2024
In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.
Read →
FDA Greenlights Aprea's Novel WEE1 Kinase Inhibitor APR-1051 for Cancer Trial
Latest Hotspot
3 min read
FDA Greenlights Aprea's Novel WEE1 Kinase Inhibitor APR-1051 for Cancer Trial
15 March 2024
Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.
Read →
Unlock the Power of Synapse: A Guide to Searching Hydrocortisone
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Hydrocortisone
15 March 2024
Hydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.